Real ‐world clinical outcomes and predictors of glycaemic and weight response to exenatide once weekly in patients with type 2 diabetes: The CIBELES project

ConclusionsIn a real‐world setting, ExQW significantly decreased A1C, weight, blood pressure and lipids at 6 months. Our study identified higher baseline A1C as the sole independent predictor of glycaemic response to ExQW and higher BMI and previous DDP4i treatment as predictive factors of meaningful weight response.

Source: International Journal of Clinical Practice - January 17, 2018 Category: Internal Medicine Authors: Juan Jos é Gorgojo‐Martínez, Manuel Angel Gargallo‐Fernández, Miguel Brito‐Sanfiel, Arturo Lisbona‐Catalán Tags: ORIGINAL PAPER Source Type: research